Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319198 · ClinicalTrials.gov registry record · Phase 4
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
A Phase 4 study of Metastatic Solid Tumors, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 20
- Study locations
NCT04319198: Completed Phase 4 study of Metastatic Solid Tumors, sponsored by Gilead Sciences.
NCT04319198 is a Phase 4 study of Metastatic Solid Tumors that has completed, run by Gilead Sciences. The registered enrollment target is 25 participants, below the 205-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04319198, a Phase 4 study of Metastatic Solid Tumors, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
Primary Outcome
An adverse event was defined as any untoward medical occurrence in a participant administered a medicinal product that does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan-hiy
Study Locations (20)
Texas
- Next Oncology - Austin
- Oncology Consultants,P.A. - Houston
- The University of Texas M.D. Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Other
- Institut Jules Bordet - Brussels
- CHU UCL NAMUR - Sainte Elisabeth - Namur
- Institut Bergonie - Bordeaux
- Centre Leon Berard - Lyon
Florida
- Florida Cancer Specialists & Research Institute - Fort Myers
- Baptist Health - Miami Cancer Institute - Miami
Illinois
- Illinois Cancer Specialists - Arlington Heights
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
California
- University of California San Francisco - San Francisco
Colorado
- Rocky Mountain Cancer Center - Aurora
Delaware
- Christiana Care Health Services, Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 4 |
What the finished NCT04319198 record still lists
NCT04319198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 205-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan-hiy is the first listed.
NCT04319198 names 20 study sites across 11 states, led by Texas, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT04319198 about?
NCT04319198 is a clinical study titled "Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy". The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
What is the current status of trial NCT04319198?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2020-08-04. Estimated completion is 2024-10-18.
What conditions does trial NCT04319198 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors.
What interventions are being tested in trial NCT04319198?
The interventions under investigation include: Sacituzumab Govitecan-hiy (DRUG).
Who is sponsoring clinical trial NCT04319198?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04319198 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04319198's enrollment target sits among peer trials
25 17th of 20 higher than 4 of 20 other Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
RECRUITING · Phase 2
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI